Roberto Iacovelli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3233480/publications.pdf

Version: 2024-02-01

216	5,005	87723	118652
papers	citations	38 h-index	62 g-index

222	222	222	7990
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis. European Journal of Cancer, 2015, 51, 587-594.	1.3	425
2	Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. New England Journal of Medicine, 2019, 381, 2506-2518.	13.9	403
3	Metabolic phenotype of bladder cancer. Cancer Treatment Reviews, 2016, 45, 46-57.	3.4	201
4	Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer, 2013, 119, 3377-3384.	2.0	170
5	Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. Targeted Oncology, 2016, 11, 143-148.	1.7	152
6	The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, e645-e653.	0.9	115
7	Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Annals of Oncology, 2015, 26, 2107-2113.	0.6	85
8	Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. Cancer Treatment Reviews, 2014, 40, 271-275.	3.4	84
9	Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma. Nature Communications, 2020, 11, 4333.	5.8	82
10	Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. British Journal of Cancer, 2013, 109, 1755-1759.	2.9	79
11	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. Annals of Surgical Oncology, 2015, 22, 2094-2100.	0.7	72
12	Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data. European Urology, 2014, 65, 713-720.	0.9	71
13	Molecular markers in circulating tumour cells from metastatic colorectal cancer patients. Journal of Cellular and Molecular Medicine, 2010, 14, 2073-2077.	1.6	69
14	Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta OncolÃ³gica, 2012, 51, 873-879.	0.8	66
15	Clinical and Pathological Features of Primary Neuroectodermal Tumor/Ewing Sarcoma of the Kidney. Urology, 2013, 82, 382-386.	0.5	65
16	Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. British Journal of Clinical Pharmacology, 2014, 77, 929-938.	1.1	65
17	Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. Cancer Treatment Reviews, 2017, 54, 68-73.	3.4	64
18	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2015, 96, 156-166.	2.0	61

#	Article	IF	Citations
19	Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. BJU International, 2012, 110, 1747-1753.	1.3	60
20	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. European Journal of Cancer, 2013, 49, 2134-2142.	1.3	60
21	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. Journal of Urology, 2015, 193, 41-47.	0.2	58
22	Chemotherapy or Targeted Therapy as Second-Line Treatment of Advanced Gastric Cancer. A Systematic Review and Meta-Analysis of Published Studies. PLoS ONE, 2014, 9, e108940.	1.1	55
23	Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma. European Urology, 2015, 68, 154-160.	0.9	53
24	DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. British Journal of Clinical Pharmacology, 2015, 80, 581-588.	1.1	52
25	Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma. British Journal of Cancer, 2014, 110, 1778-1784.	2.9	50
26	Circulating tumor cells and "suspicious objects" evaluated through CellSearchÂ® in metastatic renal cell carcinoma. Anticancer Research, 2011, 31, 4219-21.	0.5	49
27	Clinical and pathological features of primary renal synovial sarcoma: analysis of 64 cases from 11 years of medical literature. BJU International, 2012, 110, 1449-1454.	1.3	48
28	FOLFOX-4 Chemotherapy for Patients With Unresectable or Relapsed Peritoneal Pseudomyxoma. Oncologist, 2014, 19, 845-850.	1.9	48
29	Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials. International Journal of Cancer, 2015, 136, 1-10.	2.3	47
30	Immune checkpoint inhibitors and prostate cancer: a new frontier?. Oncology Reviews, 2016, 10, 293.	0.8	47
31	Patients with sarcomatoid renal cell carcinoma â€“ re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. European Journal of Cancer, 2020, 136, 195-203.	1.3	47
32	Inhibition of the VEGF/VEGFR Pathway Improves Survival in Advanced Kidney Cancer: A Systematic Review and Meta-Analysis. Current Drug Targets, 2015, 16, 164-170.	1.0	47
33	The prospect of precision therapy for renal cell carcinoma. Cancer Treatment Reviews, 2016, 49, 37-44.	3.4	46
34	Clinical outcome and prognostic factors in renal medullary carcinoma. A pooled analysis from 18 years of medical literature.. Canadian Urological Association Journal, 2015, 9, 172.	0.3	44
35	Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and metaâ€anâ€alysis of clinical trials. International Journal of Cancer, 2014, 135, 763-773.	2.3	43
36	De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. Cancer Treatment Reviews, 2018, 70, 67-74.	3.4	41

#	Article	IF	Citations
37	Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU International, 2012, 110, 692-698.	1.3	39
38	Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5â€fluorouracil: a metaâ€analysis of published trials. British Journal of Clinical Pharmacology, 2014, 78, 1228-1237.	1.1	39
39	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110196.	1.4	36
40	Adjuvant therapy in renal cell carcinoma. Cancer Treatment Reviews, 2017, 60, 152-157.	3.4	35
41	Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. Lancet Oncology, The, 2020, 21, 1513-1525.	5.1	35
42	Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. Clinical and Experimental Nephrology, 2012, 16, 464-467.	0.7	33
43	Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory,RAS-BRAFwild-type colorectal cancer receiving cetuximab or panitumumab. International Journal of Cancer, 2015, 137, 1467-1474.	2.3	33
44	The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer. European Journal of Cancer, 2015, 51, 1970-1977.	1.3	31
45	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or PoorÂPrognosis?. Clinical Genitourinary Cancer, 2018, 16, 355-359.e1.	0.9	31
46	Past, Present and Future of Targeted Therapy in Solid Tumors. Current Cancer Drug Targets, 2010, 10, 433-461.	0.8	30
47	The origin of prostate metastases: emerging insights. Cancer and Metastasis Reviews, 2015, 34, 765-773.	2.7	30
48	Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. European Journal of Cancer, 2017, 83, 237-246.	1.3	30
49	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. Clinical Genitourinary Cancer, 2018, 16, e945-e951.	0.9	30
50	Everolimus and Temsirolimus Are Not the Same Second-Line in Metastatic Renal Cell Carcinoma. A Systematic Review and Meta-Analysis of Literature Data. Clinical Genitourinary Cancer, 2015, 13, 137-141.	0.9	28
51	Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story. Cancers, 2019, 11, 1525.	1.7	28
52	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. Targeted Oncology, 2020, 15, 495-501.	1.7	28
53	Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. Oncotarget, 2015, 6, 32161-32168.	0.8	28
54	Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. Cancer and Metastasis Reviews, 2014, 33, 321-331.	2.7	27

#	Article	IF	Citations
55	Positive Association between Preoperative Total Testosterone Levels and Risk of Positive Surgical Margins by Prostate Cancer: Results in 476 Consecutive Patients Treated Only by Radical Prostatectomy. Urologia Internationalis, 2018, 101, 38-46.	0.6	27
56	Role of MGMT as biomarker in colorectal cancer. World Journal of Clinical Cases, 2014, 2, 835.	0.3	27
57	Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. Targeted Oncology, 2016, 11, 337-343.	1.7	23
58	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. Cancers, 2020, 12, 84.	1.7	22
59	Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer. Critical Reviews in Oncology/Hematology, 2016, 98, 24-28.	2.0	21
60	Cabozantinibâ€related cardiotoxicity: a prospective analysis in a realâ€world cohort of metastatic renal cell carcinoma patients. British Journal of Clinical Pharmacology, 2019, 85, 1283-1289.	1.1	21
61	Clinical management and follow-up of squamous intraepithelial cervical lesions during pregnancy and postpartum. Anticancer Research, 2007, 27, 2743-6.	0.5	21
62	The Tumor Entity Denominated â€œclear cell-papillary renal cell carcinomaâ€•According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. Pathology and Oncology Research, 2018, 24, 447-456.	0.9	20
63	Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 42-45.	0.6	20
64	Adverse events related to abiraterone and enzalutamide treatment: analysis of the EudraVigilance database and meta-analysis of registrational phase III studies. Prostate Cancer and Prostatic Diseases, 2020, 23, 199-206.	2.0	20
65	Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis. Cancer Treatment Reviews, 2021, 100, 102295.	3.4	20
66	Treatment of collecting duct carcinoma: current status and future perspectives. Anticancer Research, 2014, 34, 1027-30.	0.5	20
67	New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis. Cancer Treatment Reviews, 2022, 106, 102377.	3.4	20
68	Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. Oncotarget, 2017, 8, 7328-7335.	0.8	19
69	Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature. Clinical Genitourinary Cancer, 2018, 16, e1069-e1071.	0.9	19
70	Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. British Journal of Cancer, 2012, 107, 1227-1232.	2.9	18
71	Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status. PLoS ONE, 2014, 9, e92147.	1.1	18
72	Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer. Targeted Oncology, 2018, 13, 649-655.	1.7	18

#	Article	IF	Citations
73	Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study. Cancer Treatment and Research Communications, 2020, 22, 100161.	0.7	18
74	Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. Expert Review of Anticancer Therapy, 2011, 11, 1631-1640.	1.1	17
75	Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. Journal of Neuro-Oncology, 2013, 113, 397-401.	1.4	17
76	Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. European Journal of Cancer, 2015, 51, 473-481.	1.3	17
77	Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis. Cancer Treatment Reviews, 2018, 70, 112-117.	3.4	17
78	The development of PARP as a successful target for cancer therapy. Expert Review of Anticancer Therapy, 2018, 18, 161-175.	1.1	16
79	Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. European Urology, 2021, 80, 497-506.	0.9	16
80	Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer. Targeted Oncology, 2016, 11, 569-577.	1.7	15
81	Toward a genome-based treatment landscape for renal cell carcinoma. Critical Reviews in Oncology/Hematology, 2019, 142, 141-152.	2.0	15
82	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. Clinical Genitourinary Cancer, 2020, 18, 477-488.	0.9	15
83	Circulating tumor cells in genitourinary tumors. Therapeutic Advances in Urology, 2018, 10, 65-77.	0.9	14
84	Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis. Seminars in Oncology, 2019, 46, 65-72.	0.8	14
85	Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region. Clinical Genitourinary Cancer, 2019, 17, e187-e194.	0.9	14
86	Clinical and pathological features of primary renal angiosarcoma.. Canadian Urological Association Journal, 2014, 8, 223.	0.3	13
87	Future perspectives for personalized immunotherapy in renal cell carcinoma. Expert Opinion on Biological Therapy, 2017, 17, 1049-1052.	1.4	13
88	Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies. Expert Opinion on Biological Therapy, 2018, 18, 937-945.	1.4	13
89	Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. Journal of Translational Medicine, 2019, 17, 296.	1.8	13
90	Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. Future Oncology, 2014, 10, 1741-1750.	1.1	12

#	Article	IF	Citations
91	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. Clinical Colorectal Cancer, 2017, 16, e191-e198.	1.0	12
92	Biomarkers of response to advanced prostate cancer therapy. Expert Review of Molecular Diagnostics, 2020, 20, 195-205.	1.5	12
93	Genital and inguinal cutaneous toxicity in male and female patients treated with sunitinib. International Journal of Dermatology, 2012, 51, 221-222.	0.5	11
94	Management of Metastatic Renal Cell Carcinoma Progressed After Sunitinib or Another Antiangiogenic Treatment. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 611-615.	0.6	11
95	Prognostic Factors in Patients Receiving Third Line Targeted Therapy for Metastatic Renal Cell Carcinoma. Journal of Urology, 2015, 193, 1905-1910.	0.2	11
96	Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents. Critical Reviews in Oncology/Hematology, 2016, 99, 324-331.	2.0	11
97	The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. Immunotherapy, 2017, 9, 579-587.	1.0	11
98	Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence. Expert Review of Anticancer Therapy, 2021, 21, 1029-1054.	1.1	11
99	Tumor burden as an independent prognostic factor in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2012, 30, 397-397.	0.8	11
100	Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials. Prostate Cancer and Prostatic Diseases, 2013, 16, 323-327.	2.0	10
101	Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 541.e7-541.e13.	0.8	10
102	Cathepsin K Expression in Castration-Resistant Prostate Carcinoma: A Therapeutical Target for Patients at Risk for Bone Metastases. International Journal of Biological Markers, 2017, 32, 243-247.	0.7	10
103	Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 526.e13-526.e18.	0.8	10
104	PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer. Journal of Immunotherapy, 2019, 42, 269-273.	1.2	10
105	Verrucous carcinoma of the cervix: detection of carcinogenetic human papillomavirus types and their role during follow-up. Anticancer Research, 2007, 27, 4491-4.	0.5	10
106	Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210795.	1.4	10
107	Multimodality Treatment of Gynecomastia in Patients Receiving Antiandrogen Therapy for Prostate Cancer in the Era of Abiraterone Acetate and New Antiandrogen Molecules. Oncology, 2013, 84, 92-99.	0.9	9
108	Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. Future Oncology, 2014, 10, 1361-1372.	1.1	9

#	Article	IF	Citations
109	Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors. Anti-Cancer Drugs, 2017, 28, 206-212.	0.7	9
110	Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study. Clinical Genitourinary Cancer, 2019, 17, e150-e155.	0.9	9
111	The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?. PLoS ONE, 2015, 10, e0120427.	1.1	9
112	Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations. Cancer Treatment Reviews, 2022, 105, 102379.	3.4	9
113	Gemcitabine-Induced Extensive Skin Necrosis. Case Reports in Medicine, 2012, 2012, 1-3.	0.3	8
114	Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib.. Canadian Urological Association Journal, 2014, 8, 121.	0.3	8
115	Renal cell carcinoma in one year: Going inside the news of 2017 â€“ A report of the main advances in RCC cancer research. Cancer Treatment Reviews, 2018, 67, 29-33.	3.4	8
116	PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. Immunotherapy, 2019, 11, 921-930.	1.0	8
117	Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): The rainbow study.. Journal of Clinical Oncology, 2014, 32, 471-471.	0.8	8
118	Abiraterone acetate in castration-resistant prostate cancer. Anti-Cancer Drugs, 2012, 23, 247-254.	0.7	7
119	First line treatment of metastatic renal cell carcinoma. Cancer Biology and Therapy, 2014, 15, 19-21.	1.5	7
120	Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions. Critical Reviews in Oncology/Hematology, 2019, 139, 83-86.	2.0	7
121	Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer. Cancers, 2019, 11, 30.	1.7	7
122	The prognostic value of pain in castration-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 654-660.	2.0	7
123	MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. Journal of Clinical Pathology, 2022, 75, 39-44.	1.0	7
124	The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patientsâ€™ Age: A Systematic Review and Meta-Analysis. Journal of Immunotherapy, 2020, 43, 95-103.	1.2	7
125	Methylation study of the Paris system for reporting urinary (TPS) categories. Journal of Clinical Pathology, 2021, 74, 102-105.	1.0	7
126	Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. European Urology Oncology, 2021, 4, 274-281.	2.6	7

#	Article	IF	Citations
127	Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?. Current Drug Metabolism, 2017, 18, 692-699.	0.7	7
128	Prevalence of acetowhite areas in male partners of women affected by HPV and squamous intra-epithelial lesions (SIL) and their prognostic significance. A multicenter study. Anticancer Research, 2006, 26, 3171-4.	0.5	7
129	Dynamic contrast-enhanced magnetic resonance imaging in the early evaluation of anti-angiogenic therapy in metastatic renal cell carcinoma. Anticancer Research, 2013, 33, 5663-6.	0.5	7
130	Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?. Anticancer Research, 2022, 42, 1487-1493.	0.5	7
131	Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. Cancer Biology and Therapy, 2012, 13, 1001-1008.	1.5	6
132	Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. Canadian Urological Association Journal, 2015, 9, 263.	0.3	6
133	Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer. Future Oncology, 2016, 12, 2001-2008.	1.1	6
134	Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. Future Oncology, 2018, 14, 2559-2564.	1.1	6
135	Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 798.e17-798.e24.	0.8	6
136	Second-line treatment in renal cell carcinoma: clinical experience and decision making. Therapeutic Advances in Urology, 2021, 13, 175628722110228.	0.9	6
137	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. Targeted Oncology, 2021, 16, 625-632.	1.7	6
138	A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.. Journal of Clinical Oncology, 2019, 37, 148-148.	0.8	6
139	Follow-up of high-grade squamous intra-epithelial lesions (H-SIls) in human immunodeficiency virus (HIV)-positive and human papillomavirus (HPV)-positive women. analysis of risk factors. Anticancer Research, 2006, 26, 3167-70.	0.5	6
140	Targeted treatments in advanced renal cell carcinoma: focus on axitinib. Pharmacogenomics and Personalized Medicine, 2014, 7, 107.	0.4	5
141	Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma. Therapeutic Advances in Urology, 2015, 7, 286-294.	0.9	5
142	The effect of a treatment delay on outcome in metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 529.e1-529.e7.	0.8	5
143	Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.. Journal of Clinical Oncology, 2017, 35, 5030-5030.	0.8	5
144	Time from Nephrectomy as a Prognostic Factor in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapies: Overall Results from a Large Cohort of Patients. Oncology, 2015, 88, 133-138.	0.9	4

#	Article	IF	Citations
145	Renal Toxicity in Patients Treated with Anti-Pd-1 Targeted Agents for Solid Tumors. Journal of Onco-Nephrology, 2017, 1, 132-142.	0.3	4
146	De Novo, Progressed, and Neglected Metastatic Castration-Sensitive Prostate Cancer: Is One Therapy Fit for All?. Clinical Genitourinary Cancer, 2018, 16, 482-484.	0.9	4
147	Prevalence of Prostate Cancer at Different Clinical Stages in Italy: Estimated Burden of Disease Based on a Modelling Study. Biology, 2021, 10, 210.	1.3	4
148	Fecal microbiota transplantation for TKI-induced diarrhea in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2019, 37, 615-615.	0.8	4
149	Relationship and Predictive Role of the Dual Expression of FGFR and IL-8 in Metastatic Renal Cell Carcinoma Treated with Targeted Agents. Anticancer Research, 2018, 38, 3105-3110.	0.5	4
150	The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer. Anticancer Research, 2022, 42, 165-172.	0.5	4
151	Emerging tyrosine kinase inhibitors for the treatment of renal cancer. Expert Opinion on Emerging Drugs, 2015, 20, 379-392.	1.0	3
152	Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience. Anticancer Research, 2018, 38, 4913-4918.	0.5	3
153	CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology, 2019, 30, v882-v883.	0.6	3
154	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. Expert Review of Cardiovascular Therapy, 2019, 17, 917-927.	0.6	3
155	NIVES study: A phase II trial of nivolumab (NIVO) plus stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2018, 36, TPS4602-TPS4602.	0.8	3
156	Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study.. Journal of Clinical Oncology, 2020, 38, 16-16.	0.8	3
157	Dermatomyositis as first clinical appearance for a thymic epidermoid cell carcinoma. Acta Biomedica, 2010, 81, 68-71.	0.2	3
158	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. Journal of Personalized Medicine, 2022, 12, 727.	1.1	3
159	Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib. Clinical Genitourinary Cancer, 2022, 20, 498.e1-498.e9.	0.9	3
160	Neo-adjuvant and adjuvant chemotherapy in bladder cancer. Annals of Oncology, 2007, 18, vi162-vi163.	0.6	2
161	Is It Possible to Optimize the use of Targeted Therapies in the Treatment of Renal Cell Carcinoma?. Tumori, 2010, 96, 794-795.	0.6	2
162	Post-docetaxel therapy in castration resistant prostate cancer â€“ the forest is growing in the desert. Therapeutic Advances in Urology, 2012, 4, 107-111.	0.9	2

#	Article	IF	Citations
163	Study design and clinical evidence in mRCC. Cancer Biology and Therapy, 2014, 15, 486-488.	1.5	2
164	Bevacizumab treatment in the elderly patient with metastatic colorectal cancer. Clinical Interventions in Aging, 2015, 10, 127.	1.3	2
165	Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib. Therapeutic Advances in Urology, 2015, 7, 59-68.	0.9	2
166	Sunitinib 2 weeks on, 1 off: strengths and weaknesses. Annals of Oncology, 2015, 26, 1511-1512.	0.6	2
167	Drug-drug interactions between abiraterone (ABI) or enzalutamide (ENZ) and concomitant medications in patients with metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology, 2016, 27, iv34.	0.6	2
168	Correlation between immuno-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study. Annals of Oncology, 2018, 29, viii316.	0.6	2
169	The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. Anti-Cancer Drugs, 2018, 29, 705-709.	0.7	2
170	Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC). Annals of Oncology, 2019, 30, v372-v373.	0.6	2
171	2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma. Expert Review of Anticancer Therapy, 2021, 21, 1203-1206.	1.1	2
172	Changes in tumor burden and IMDC class after active surveillance (AS) for metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2017, 35, 435-435.	0.8	2
173	Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.. Journal of Clinical Oncology, 2020, 38, 5559-5559.	0.8	2
174	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. World Journal of Clinical Oncology, 2021, 12, 1037-1046.	0.9	2
175	Renal Cell Carcinoma: Incidence and Cost Estimation in the Era of Targeted Therapy. Tumori, 2010, 96, 361-361.	0.6	1
176	Neoadjuvant targeted therapy in renal cell carcinoma. Nature Reviews Urology, 2010, 7, 1-1.	1.9	1
177	FOLFIRI with cetuximab or bevacizumab: FIRE-3. Lancet Oncology, The, 2014, 15, e581.	5.1	1
178	Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP). Annals of Oncology, 2017, 28, v319-v320.	0.6	1
179	ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance. Pathology Research and Practice, 2018, 214, 1675-1680.	1.0	1
180	Positive Association between Preoperative Total Testosterone and Lymph Node Invasion in Intermediate Risk Prostate Cancer. Current Urology, 2019, 12, 216-222.	0.4	1

#	Article	IF	Citations
181	Cabozantinib-related pneumothorax in rapidly responding patients with renal cell carcinoma. Lancet Oncology, The, 2019, 20, e124.	5.1	1
182	Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document. Cancers, 2019, 11, 1908.	1.7	1
183	629P Neutrophil-lymphocyte ratio (NLR) as a prognostic and predictive biomarker in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) vs abiraterone or enzalutamide in the CARD study. Annals of Oncology, 2020, 31, S519-S520.	0.6	1
184	Inside prostate cancer news from the 2021 ASCO Genitourinary Cancers Symposium. Expert Review of Anticancer Therapy, 2021, 21, 1-4.	1.1	1
185	Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2013, 31, 431-431.	0.8	1
186	CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide.. Journal of Clinical Oncology, 2020, 38, 5569-5569.	0.8	1
187	Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).. Journal of Clinical Oncology, 2020, 38, TPS762-TPS762.	0.8	1
188	Renal cell carcinoma: incidence and cost estimation in the era of targeted therapy. Tumori, 2010, 96, 361.	0.6	1
189	Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma?. Tumori, 2010, 96, 794-5.	0.6	1
190	Hepatocellular carcinoma in Central, Eastern, and Southern Europe. What Future after the SHARP Trial?. Open Medicine (Poland), 2009, 4, 138-139.	0.6	0
191	The End of Chemotherapy in Renal Cell Carcinoma: For Much But Not for All. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 522-523.	0.6	0
192	Umbilical Node as First Clinical Appearance in a Patient with a High Tumor Burden. American Surgeon, 2011, 77, 248-249.	0.4	0
193	Reply to â€œmTOR inhibitor-related pulmonary toxicity; incidence even higherâ€• Acta OncolÃ³gica, 2013, 52, 1235-1235.	0.8	0
194	Salvage therapy for recurrence of bladder cancer: do we need a uniform approach?. Expert Review of Clinical Pharmacology, 2014, 7, 397-399.	1.3	0
195	Modified BEP chemotherapy in patients with testicular germ-cell tumors treated at a Comprehensive Cancer Center. Annals of Oncology, 2016, 27, iv29.	0.6	0
196	Re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970â€“8. European Urology, 2017, 71, e175-e176.	0.9	0
197	CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure. Annals of Oncology, 2017, 28, vi17.	0.6	0
198	Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study). Annals of Oncology, 2019, 30, v333.	0.6	0

#	Article	IF	Citations
199	Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer. Annals of Oncology, 2021, 32, 1192-1193.	0.6	0
200	Prognostic role of body composition parameters in renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2012, 30, 4621-4621.	0.8	0
201	Overall survival (OS) in metastatic renal cell carcinoma (mRCC) sequentially treated with different targeted therapies (TTs): Results from a large cohort of patients.. Journal of Clinical Oncology, 2012, 30, 4629-4629.	0.8	0
202	Clinical outcome (CO) and predictive factors (PRE) evaluation of young (â‰¤ 60 years) castration-resistant prostate cancer (CRPC) patients, treated with docetaxel (DOC): Preliminary results of an Italian multicenter retrospective study (CYCLOP study).. Journal of Clinical Oncology, 2013, 31, e16031-e16031.	0.8	0
203	Rationale and Protocol of SOAP: A Phase II Study to Evaluate the Efficacy of Sorafenib as Second-Line Treatment after Pazopanib in Patients with Advanced Renal Cell Carcinoma. Tumori, 2014, 100, e282-e285.	0.6	0
204	Prognostic value of flare-up phenomenon after discontinuation of sunitinib (SU) or pazopanib (PA) in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2014, 32, 448-448.	0.8	0
205	Patients with metastatic castration-resistant prostate cancer (mCRPC) are primary resistant (PR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA.. Journal of Clinical Oncology, 2017, 35, e585-e585.	0.8	0
206	Patients with metastatic castration-resistant prostate cancer (mCRPC) who are long-term responders (LTR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA.. Journal of Clinical Oncology, 2017, 35, 254-254.	0.8	0
207	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in pts with metastatic castration-resistant prostate cancer (mCRPC) receiving a new agent (NA)- based third-line treatment: Final results from a multicenter Italian study.. Journal of Clinical Oncology, 2017, 35, 230-230.	0.8	0
208	Localized prostate cancer genotyping: another step towards personalized therapy. Translational Cancer Research, 2017, 6, S246-S248.	0.4	0
209	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)- based third line treatment: Final results from a multicenter Italian study.. Journal of Clinical Oncology, 2017, 35, e16521-e16521.	0.8	0
210	The impact of kidney function on the efficacy and safety of pazopanib in metastatic renal cell carcinoma (mRCC) patients: CORE-URO-01 study.. Journal of Clinical Oncology, 2017, 35, e16063-e16063.	0.8	0
211	A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.. Journal of Clinical Oncology, 2019, 37, 5050-5050.	0.8	0
212	Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer PD-L1+ unfit for cisplatin: The ARIES study.. Journal of Clinical Oncology, 2020, 38, TPS596-TPS596.	0.8	0
213	Enzalutamide (E) re-challenge as second-line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with first-line enzalutamide + docetaxel (D): Preliminary results of a post-progression analysis of CHEIRON trial.. Journal of Clinical Oncology, 2020, 38, 123-123.	0.8	0
214	PD16-08â€ƒEFFECT OF CABAZITAXEL VS ABIRATERONE OR ENZALUTAMIDE ON PATIENT-REPORTED OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A PRE-PLANNED EQ-5D-5L ANALYSIS OF THE CARD STUDY. Journal of Urology, 2020, 203, .	0.2	0
215	Umbilical node as first clinical appearance in a patient with a high tumor burden. American Surgeon, 2011, 77, E248-9.	0.4	0
216	Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma. Tumori, 2014, 100, e282-5.	0.6	0